Who are BMS-790052 (Daclatasvir)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): EBR/GZR, EBR/GZR (elbasvir/grazoprevir), Mavyret, PIBRENTASVIR, Zepatier, Daklinza.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bms-790052-daclatasvir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

BMS-790052 (Daclatasvir) — Competitive Intelligence Brief

BMS-790052 (Daclatasvir) (BMS-790052 (Daclatasvir)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NS5A inhibitor. Area: Virology/Infectious Disease.

phase 3 NS5A inhibitor Hepatitis C virus NS5A protein Virology/Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

BMS-790052 (Daclatasvir) (BMS-790052 (Daclatasvir)) — Bristol-Myers Squibb. Daclatasvir inhibits the hepatitis C virus NS5A protein, blocking viral replication and spread.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BMS-790052 (Daclatasvir) TARGET	BMS-790052 (Daclatasvir)	Bristol-Myers Squibb	phase 3	NS5A inhibitor	Hepatitis C virus NS5A protein
EBR/GZR	EBR/GZR	Dallas VA Medical Center	marketed	Direct-acting antiviral combination (NS5A inhibitor + NS3/4A protease inhibitor)	Hepatitis C virus NS5A protein and NS3/4A serine protease
EBR/GZR (elbasvir/grazoprevir)	EBR/GZR (elbasvir/grazoprevir)	University of Florida	marketed	Direct-acting antiviral (DAA) combination; NS5A inhibitor + NS3/4A protease inhibitor	Hepatitis C virus NS5A protein and NS3/4A serine protease
Mavyret	GLECAPREVIR	AbbVie	marketed	Hepatitis C Virus NS5A Inhibitor [EPC]		2017-01-01
PIBRENTASVIR	PIBRENTASVIR		marketed	Hepatitis C Virus NS5A Inhibitor [EPC]		2017-01-01
Zepatier	ELBASVIR	Merck & Co.	marketed	Hepatitis C Virus NS5A Inhibitor [EPC]		2016-01-01
Daklinza	DACLATASVIR	Bristol-Myers Squibb	marketed	Hepatitis C Virus NS5A Inhibitor	Potassium voltage-gated channel subfamily H member 2	2015-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-07-24 — Zepatier · 7973040 · US
2030-06-10 — Mavyret · 10039754 · US
2030-06-10 — Mavyret · 10028937 · US
2030-11-06 — Mavyret · 9586978 · US
2030-12-10 — Mavyret · 10039754*PED · US
2030-12-10 — Mavyret · 10028937*PED · US
2031-05-04 — Zepatier · 8871759 · US
2031-05-06 — Mavyret · 9586978*PED · US
2032-01-19 — Mavyret · 8648037 · US
2032-05-18 — Mavyret · 8937150 · US
2032-07-19 — Mavyret · 8648037*PED · US
2032-11-18 — Mavyret · 8937150*PED · US
2034-03-14 — Mavyret · 11484534 · US
2034-03-14 — Mavyret · 10286029 · US
2034-09-14 — Mavyret · 10286029*PED · US
2034-09-14 — Mavyret · 11484534*PED · US
2035-05-08 — Mavyret · RE48923 · US
2035-06-05 — Mavyret · 9321807 · US
2035-11-08 — Mavyret · RE48923*PED · US
2035-12-05 — Mavyret · 9321807*PED · US
2036-06-24 — Mavyret · 11246866 · US
2036-12-24 — Mavyret · 11246866*PED · US

Sponsor landscape (NS5A inhibitor class)

Bristol-Myers Squibb · 2 drugs in this class
AbbVie · 1 drug in this class
Ferrer Internacional S.A. · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BMS-790052 (Daclatasvir) — Competitive Intelligence Brief. https://druglandscape.com/ci/bms-790052-daclatasvir. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab